Stephen Hanson, PhD, MBA
Business Development Director, Spiderwort Inc.
LinkedIn Profile: [Stephen Hanson - LinkedIn](https://ca.linkedin.com/in/stephen-hanson-27584227)
Experience and Expertise:
Dr. Stephen Hanson is the Business Development Director at Spiderwort Inc., a biotech company specializing in cellulose-based biomaterials for regenerative medicine. Dr. Hanson brings a unique blend of experience in both science and business, underpinned by his academic and professional credentials:
- PhD in Medical Sciences (Infection and Immunity)
- MBA specializing in Management of New and Innovative Technologies (MINT)
- CIHR Science to Business (S2B) Fellow
Dr. Hanson's career spans across biotech companies, Network Centres of Excellence (NCEs), and academic technology transfer, highlighting his capacity to bridge scientific innovation with commercial viability.
Achievements and Contributions:
1. Fundraising and Strategic Partnerships:
- Played a critical role in Spiderwort's progression through the Creative Destruction Lab (CDL) program.
- Integral to the seed round fundraising process and ongoing development of strategic partnerships.
- Actively supports Spiderwort in expanding its business development team and securing essential funding for clinical translation of biomaterials.
2. Industry Engagement:
- Attended the Biotechnology Innovation Organization (BIO) 2022 conference in San Diego to present and discuss Spiderwort's advancements in cellulose-based biomaterials.
- Participated in BIOTECanada Coast-to-Coast Pitch Competition, showcasing Spiderwort’s innovative technologies.
- Recently selected to join the prestigious adMare Academy Executive Institute, designed to foster leadership in Canada's life sciences ecosystem. He is among the 20 participants chosen annually to enhance skills and leadership, furthering both his own development and Spiderwort's strategic goals.
Company Overview: Spiderwort Inc.
Headquarters:
- 7 Bayview Station Road, Ottawa, Ontario, K1Y 2C5
- 283, boulevard Alexandre-Taché (F3006), Gatineau, Québec, J9A 1L8
Technology Innovations:
- CelluBridge: Aims at spinal cord injury treatments.
- CelluJuve: Focused on soft tissue regeneration.
Leadership Team:
- Charles M. Cuerrier, PhD: Chief Executive Officer | Co-founder
- Andrew E. Pelling, PhD, FRSB: Chief Scientific Officer | Co-founder
- Scott Jarvis, CPA: Chief Financial Officer
Spiderwort Inc. is at the forefront of developing transformative cellulose-based biomaterials, aiming to create scaffolding for future regenerative medical practices. The company's core technologies have received significant attention, including a Breakthrough Device Designation from the U.S. FDA for its CelluBridge technology in spinal cord injury treatment.
Professional Network and Contributions:
Dr. Hanson maintains an active presence on LinkedIn, where he frequently shares updates on Spiderwort’s achievements and milestones. His contributions to the field and proactive industry engagements underscore his commitment to advancing biotechnological innovations and fostering meaningful collaborations.
Contact Information:
- Email: [Shannon Murphy, Media Contact](mailto:s.murphy@spiderwortbio.com)
- Phone: 613-808-5939
Dr. Stephen Hanson's leadership and multifaceted expertise position him as a pivotal member of Spiderwort Inc., driving forward both the company’s strategic initiatives and its groundbreaking work in the field of regenerative medicine.
